Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Global phase 2 study will evaluate safety and efficacy of DS-8201 in patients with unresectable and/or metastatic non-squamous HER2-overexpressing or HER2-mutated non-small cell lung cancer- Curre...
Page (1) of 1 - 05/31/18||
(May 31, 2018)
This article is no longer available,but here are some related topics.
USA,Japan, Inc.,Medicine,Disease,Cancer,Surgery,Womens Health,Nurse,Science,Lifestyle,Medical,Cancer,Science,Other,Medical Professionals,Men,Women,
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved